Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Sales (2018 - 2025)

X4 Pharmaceuticals' Return on Sales history spans 7 years, with the latest figure at 9.32% for Q4 2025.

  • For Q4 2025, Return on Sales rose 1845.0% year-over-year to 9.32%; the TTM value through Dec 2025 reached 2.26%, up 1239.0%, while the annual FY2025 figure was 2.26%, 1239.0% up from the prior year.
  • Return on Sales reached 9.32% in Q4 2025 per XFOR's latest filing, up from 16.89% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 161.34% in Q2 2024 to a low of 65.53% in Q3 2024.
  • Average Return on Sales over 4 years is 21.65%, with a median of 21.66% recorded in 2023.
  • Peak YoY movement for Return on Sales: skyrocketed 12147bps in 2024, then plummeted -17438bps in 2025.
  • A 4-year view of Return on Sales shows it stood at 25.44% in 2022, then soared by 259bps to 91.22% in 2023, then crashed by -130bps to 27.77% in 2024, then soared by 66bps to 9.32% in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Return on Sales are 9.32% (Q4 2025), 16.89% (Q3 2025), and 13.05% (Q2 2025).